First randomised trial backs safety of common heart drugs in COVID-19 patients

September 1, 2020
Heart patients hospitalised with COVID-19 can safely continue taking angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs), according to the BRACE CORONA trial presented in a Hot Line session today at ESC Congress 2020.ACE inhibitors and ARBs are commonly taken by heart patients to reduce blood pressure and to treat heart failure. There is conflicting observational evidence about the potential clinical impact of ACE inhibitors and ARBs on patients with COVID-19. Read more
Reading level: Grade 12
EurekAlert!, the online, global news service operated by AAAS, the science society
Please Give Us Feedback!

Why are you reading this article? (check all that apply)







How do you feel about science?







Send Feedback
Free science fair projects.